Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: Nature. 2014 May 21;510(7504):283–287. doi: 10.1038/nature13320

Extended Data Figure 9. SMYD3 depletion augments the effects of the MEK1/2 inhibitor Trametinib (GSK1120212) in Ras-driven cancer cells.

Extended Data Figure 9

a-c, Relative cell proliferation rates (bottom panel) of murine LAC cell line LKR10 (a), human LAC cell line A549 (b), or human PDAC cell line CFPac1 (c) with or without SMYD3 depletion by stable shRNA (SMYD3 proteins levels are shown in top panel) in response to the indicated doses of Trametinib. Experiments shown represent an average of 3 independent experiments performed in triplicates for each cancer line. Values represent the number of cells relative to control shRNA cells without treatment at 48hrs. b, Constitutively active MEK1 (MEK1DD) increases EGF-mediated ERK1/2 activation in SMYD3 depleted-cells. Immunoblot analysis with the indicated antibodies using lysates from A549 cells stably expressing shControl or shSMYD3 and transfected with HA-MEK1DD. Stimulation: EGF treatment for 15min at 25ng/μl.